399 related articles for article (PubMed ID: 29429376)
61. The challenge of Bacillus Calmette-Guérin failure in nonmuscle invasive bladder cancer--what is the next step in management?
Lotan Y
J Urol; 2013 Sep; 190(3):832-3. PubMed ID: 23791573
[No Abstract] [Full Text] [Related]
62. [Immunotherapy of superficial bladder cancer].
Schmitz-Dräger BJ; Schattka SO; Ebert T
Urologe A; 1993 Sep; 32(5):374-81. PubMed ID: 8212422
[TBL] [Abstract][Full Text] [Related]
63. [Percutaneous Bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ].
Yamashita S; Yogi Y; Taniguchi K; Morimitsu H; Suzu H; Kanetake H; Saito Y; Kubota S
Hinyokika Kiyo; 1992 Oct; 38(10):1095-9. PubMed ID: 1481770
[TBL] [Abstract][Full Text] [Related]
64. [Bladder carcinoma 1: Radical cystectomy, neoadjuvant and adjuvant therapy modalities].
Lampel A; Thüroff JW
Urologe A; 1998 Jan; 37(1):93-101. PubMed ID: 9540194
[No Abstract] [Full Text] [Related]
65. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
66. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy.
Zapatero A; Martin De Vidales C; Arellano R; Ibañez Y; Bocardo G; Perez M; Rabadan M; García Vicente F; Cruz Conde JA; Olivier C
Urology; 2012 Nov; 80(5):1056-62. PubMed ID: 22999456
[TBL] [Abstract][Full Text] [Related]
67. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
May M; Helke C; Nitzke T; Vogler H; Hoschke B
Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
[TBL] [Abstract][Full Text] [Related]
68. Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert's panel. Spanish Association of Urology.
Fernández-Gómez JM; Carballido-Rodríguez J; Cozar-Olmo JM; Palou-Redorta J; Solsona-Narbón E; Unda-Urzaiz JM;
Actas Urol Esp; 2013; 37(7):387-94. PubMed ID: 23773824
[TBL] [Abstract][Full Text] [Related]
69. A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy.
Baumann BC; Guzzo TJ; He J; Keefe SM; Tucker K; Bekelman JE; Hwang WT; Vaughn DJ; Malkowicz SB; Christodouleas JP
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):81-8. PubMed ID: 22543204
[TBL] [Abstract][Full Text] [Related]
70. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
[TBL] [Abstract][Full Text] [Related]
71. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
72. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
73. Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder.
Keegan KA; Resnick MJ; Clark PE
Curr Opin Oncol; 2012 May; 24(3):278-83. PubMed ID: 22273550
[TBL] [Abstract][Full Text] [Related]
74. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
[TBL] [Abstract][Full Text] [Related]
75. Role of immunotherapy in bladder cancer.
Rhea LP; Mendez-Marti S; Kim D; Aragon-Ching JB
Cancer Treat Res Commun; 2021; 26():100296. PubMed ID: 33421822
[TBL] [Abstract][Full Text] [Related]
76. [Non-muscle-invasive high-grade bladder cancer].
Gakis G; Stenzl A; Horn T; Gschwend JE; Otto W; Burger M
Urologe A; 2015 Apr; 54(4):491-8. PubMed ID: 25802103
[TBL] [Abstract][Full Text] [Related]
77. [Diagnosis of and therapy for non-muscle-invasive bladder cancer - state of the art].
Kausch von Schmeling I
Aktuelle Urol; 2010 Sep; 41(5):307-15. PubMed ID: 20824576
[TBL] [Abstract][Full Text] [Related]
78. New agents for bacillus Calmette-Guérin-refractory nonmuscle invasive bladder cancer.
Ahn JJ; Ghandour RA; McKiernan JM
Curr Opin Urol; 2014 Sep; 24(5):540-5. PubMed ID: 24921906
[TBL] [Abstract][Full Text] [Related]
79. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer.
Smaldone MC; Gayed BA; Tomaszewski JJ; Gingrich JR
Minerva Urol Nefrol; 2009 Jun; 61(2):71-89. PubMed ID: 19451890
[TBL] [Abstract][Full Text] [Related]
80. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.
Zargar-Shoshtari K; Kongnyuy M; Sharma P; Fishman MN; Gilbert SM; Poch MA; Pow-Sang JM; Spiess PE; Zhang J; Sexton WJ
World J Urol; 2016 Nov; 34(11):1567-1573. PubMed ID: 27072536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
